These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15145321)

  • 1. Leukotrienes and atherosclerosis: new roles for old mediators.
    Jala VR; Haribabu B
    Trends Immunol; 2004 Jun; 25(6):315-22. PubMed ID: 15145321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
    Sharma JN; Mohammed LA
    Inflammopharmacology; 2006 Mar; 14(1-2):10-6. PubMed ID: 16835707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of cysteinyl leukotrienes in chronic inflammation and neoplasia of the intestine].
    Broom OJ; Nielsen OH
    Ugeskr Laeger; 2009 Jan; 171(4):243-6. PubMed ID: 19174041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Leukotrienes: potential therapeutic targets in cardiovascular diseases].
    Bäck M
    Bull Acad Natl Med; 2006 Oct; 190(7):1511-8; discussion 1518-21. PubMed ID: 17450683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues.
    Norel X; Brink C
    Pharmacol Ther; 2004 Jul; 103(1):81-94. PubMed ID: 15251228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandins and leukotrienes: advances in eicosanoid biology.
    Funk CD
    Science; 2001 Nov; 294(5548):1871-5. PubMed ID: 11729303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Leukotrienes as inflammation mediators].
    Woszczek G; Pawliczak R; Kowalski ML
    Postepy Hig Med Dosw; 2003; 57(5):593-610. PubMed ID: 14737972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
    Yacoubian S; Serhan CN
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation.
    Rådmark O
    Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1140-2. PubMed ID: 12857716
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.
    Narushima S; DiMeo D; Tian J; Zhang J; Liu D; Berg DJ
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G477-88. PubMed ID: 18048478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid inflammatory mediators in diabetic vascular disease.
    Natarajan R; Nadler JL
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1542-8. PubMed ID: 15166011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid inflammatory mediators: leukotrienes, prostaglandins, platelet-activating factor.
    Christie PE; Henderson WR
    Clin Allergy Immunol; 2002; 16():233-54. PubMed ID: 11577541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukocyte recognition and metabolism of leukotrienes.
    Goetzl EJ
    Fed Proc; 1983 Nov; 42(14):3128-31. PubMed ID: 6313435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel omega -- 3-derived local mediators in anti-inflammation and resolution.
    Serhan CN
    Pharmacol Ther; 2005 Jan; 105(1):7-21. PubMed ID: 15626453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional functions for the cysteinyl leukotrienes recognized through studies of inflammatory processes in null strains.
    Austen KF
    Prostaglandins Other Lipid Mediat; 2007 May; 83(3):182-7. PubMed ID: 17481553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Roles of leukotrienes in immunological and allergic disorders].
    Yokomizo T
    Nihon Rinsho; 2005 May; 63 Suppl 5():47-52. PubMed ID: 15954323
    [No Abstract]   [Full Text] [Related]  

  • 17. Roles of lipid mediators in kidney injury.
    Hao CM; Breyer MD
    Semin Nephrol; 2007 May; 27(3):338-51. PubMed ID: 17533010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Roles of lipid mediators in controlling vascular inflammation and the progression of atherosclerosis].
    Endo J; Arita M
    Nihon Rinsho; 2011 Jan; 69(1):34-8. PubMed ID: 21226257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory signaling through leukotriene receptors in atherosclerosis.
    Bäck M
    Curr Atheroscler Rep; 2008 Jun; 10(3):244-51. PubMed ID: 18489853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of atherosclerotic plaque inflammation.
    Bäck M; Weber C; Lutgens E
    J Intern Med; 2015 Nov; 278(5):462-82. PubMed ID: 25823439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.